Betocchi S, Piscione F, Losi M A, Pace L, Boccalatte M, Perrone-Filardi P, Briguori C, Manganelli F, Ciampi Q, Salvatore M, Chiariello M
Department of Cardiology and Cardiac Surgery, Federico II University School of Medicine, Naples, Italy.
Am J Cardiol. 1996 Aug 15;78(4):451-7. doi: 10.1016/s0002-9149(96)00336-0.
Hypertrophic cardiomyopathy (HC) is characterized by impaired diastolic function, and left ventricular (LV) outflow tract obstruction in about one-fourth of patients. Verapamil improves diastolic properties, but may have dangerous adverse effects. This study investigates the effects of diltiazem on hemodynamics and LV function in 16 patients with HC who were studied with cardiac catheterization and simultaneous radionuclide angiography. Studies were performed during atrial pacing (15 beats above spontaneous rhythm) at baseline and during intravenous diltiazem administration (0.25 mg x kg(-1) over 2 minutes, and 0.014 mg x kg(-1) x min(-1). Diltiazem induced a systemic vasodilation (cardiac index: 3.4 +/- 1.0 to 4.0 +/- 1.0 L x min(-1) x m(-2), p = 0.003; aortic systolic pressure: 116 +/- 16 to 107 +/- 19 mm Hg, p = 0.007; systemic resistance index: 676 +/- 235 to 532 +/- 193 dynes x s x cm(-5) x m(-2), p = 0.006), not associated with changes in the LV outflow tract gradient. The end-systolic pressure/volume ratio decreased (30 +/- 42 to 21 +/- 29 mm Hg x ml(-1) x m(-2); p = 0.044). Pulmonary artery wedge pressure (11 +/- 5 to 15 +/- 6 mm Hg, p = 0.006), and peak filling rate increased (4.1 +/- 1.3 to 6.0 +/- 2.4 stroke counts x s(-1), p = 0.004). The time constant of isovolumetric relaxation tau decreased (74 +/- 40 to 59 +/- 38 ms, p = 0.045). The constant of LV chamber stiffness did not change. Thus, active diastolic function is improved by the acute administration of diltiazem by both direct action and changes in hemodynamics and loading conditions. LV outflow tract gradient does not increase despite systemic vasodilation. In some patients, however, a marked increase in obstruction and a potentially harmful elevation in pulmonary artery wedge pressure do occur. Passive diastolic function is not affected.
肥厚型心肌病(HC)的特征是舒张功能受损,约四分之一的患者存在左心室(LV)流出道梗阻。维拉帕米可改善舒张特性,但可能有危险的不良反应。本研究调查了地尔硫䓬对16例HC患者血流动力学和左心室功能的影响,这些患者接受了心导管检查和同步放射性核素血管造影。研究在基线时心房起搏(比自发心律快15次)期间以及静脉注射地尔硫䓬期间进行(2分钟内注射0.25mg/kg(-1),然后以0.014mg/kg(-1)·min(-1)的速度注射)。地尔硫䓬引起全身血管舒张(心脏指数:3.4±1.0至4.0±1.0L·min(-1)·m(-2),p = 0.003;主动脉收缩压:116±16至107±19mmHg,p = 0.007;全身阻力指数:676±235至532±193达因·s·cm(-5)·m(-2),p = 0.006),且与左心室流出道梯度变化无关。收缩末期压力/容积比值降低(30±42至21±29mmHg·ml(-1)·m(-2);p = 0.044)。肺动脉楔压升高(11±5至15±6mmHg,p = 0.006),峰值充盈率增加(4.1±1.3至6.0±2.4次搏动/s,p = 0.004)。等容舒张时间常数τ降低(74±40至59±38ms,p = 0.045)。左心室腔硬度常数未改变。因此,急性给予地尔硫䓬通过直接作用以及血流动力学和负荷条件的改变改善了主动舒张功能。尽管全身血管舒张,但左心室流出道梯度并未增加。然而,在一些患者中,梗阻会显著增加,肺动脉楔压会出现潜在有害的升高。被动舒张功能不受影响。